FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

FDA Revokes 2 Covid-19 Tests

Federal Register notice: FDA revokes the Emergency Use Authorizations issued for two Covid-19 diagnostics Babson Diagnostics for the Babson Diagnosti...

latest-news-card-1
Human Drugs

FDA Accepts BioMarin Voxzogo New Indication sBLA

FDA will review a BioMarin sBLA to expand the approved achondroplasia treatment indication for Voxzogo to include children under age 5.

latest-news-card-1
Human Drugs

Covis Willing to Voluntarily Withdraw Makena

Covis Pharma says it is willing to work with CDER on an orderly withdrawal of Makena from the market.

latest-news-card-1
Human Drugs

FDAs Cancer Patient-Focused Glossary

Six Oncology Center of Excellence staff members describe the process used in developing a new patient-focused glossary of cancer clinical trial terms.

latest-news-card-1
Human Drugs

USP Launches Nitrosamines Analytical Hub

The United States Pharmacopeia launches its Nitrosamines Analytical Hub to help address the nitrosamine crisis in the U.S.

latest-news-card-1
FDA General

FDA Bioresearch Inspection Findings Out

FDA annual inspection metrics from its Bioresearch Monitoring program show that the most common clinical investigator inspectional observations involv...

latest-news-card-1
Medical Devices

First Covid Test Authorized Outside of an EUA

FDA grants Quidel a de novo marketing authorization for its Sofia 2 SARS Antigen+ FIA, Sofia SARS Antigen FIA Control Swab Set, which is the first tes...

Human Drugs

Determine NMN is a Dietary Supplement: Petition

Two natural product stakeholders petition FDA to determine that nicotinamide mononucleotide can legally be a dietary supplement.

latest-news-card-1
Federal Register

Lithium Citrate Not Withdrawn Due to Safety/Efficacy

Federal Register notice: FDA determines that a Hikma Pharmaceuticals NDA for lithium citrate oral solution was not withdrawn due to safety or effectiv...

latest-news-card-1
Human Drugs

FDA Extends Review Date for BioMarins Roctavian

FDA extends to 6/30 the PDUFA action date for BioMarins Roctavian gene therapy for adults with severe hemophilia A.